BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

Volver

Resultados 56 resultados LastUpdate Última actualización 24/05/2018 [18:40:00] pdf PDF




Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 3 nextPage   Mostrar por página


IN VITRO DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE BASED ON THE ALBUMIN REDOX LEVEL IN THE CEREBROSPINAL FLUID

NºPublicación: EP3324188A1 23/05/2018

Solicitante:
GRIFOLS WORLDWIDE OPERATIONS LTD [IE]

Resumen de: EP3324188A1

In vitro diagnostic method for Alzheimer's disease, based on the albumin redox level in the cerebrospinal fluid. The present invention relates to an in vitro diagnostic method for diagnosing Alzheimer's disease (AD), comprising the steps of: a) determining the content of mercaptoalbumin (HMA) in a sample of cerebrospinal fluid (CSF); and b) comparing the content determined with the content of HMA in CSF in healthy subjects. If the HMA content is less than that of the healthy subjects, it is indicative of AD. In an embodiment, the HMA level is also determined in blood or plasma and a difference or ratio is calculated.



traducir


 

HUMANIZED ANTIBODIES

NºPublicación: EP3322723A2 23/05/2018

Solicitante:
PROBIODRUG AG [DE]

Resumen de: WO2017009459A2

The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (Αβ N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of Αβ N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.



traducir


 

ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF

NºPublicación: EP3322442A2 23/05/2018

Solicitante:
H LUNDBECK AS [DK]

Resumen de: WO2017009308A2

The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.



traducir


 

METHOD FOR THE PRESELECTION OF DRUGS FOR PROTEIN MISFOLDING DISEASES

NºPublicación: EP3324186A1 23/05/2018

Solicitante:
RUHR UNIV BOCHUM [DE]

Resumen de: EP3324186A1

The invention provides a method that gives direct information about the intervention of a potential drug on the secondary structure distribution of a target biomolecule, i.e., for a disease with misfolded protein, such as neurodegenerative diseases. The secondary structural change is monitored by vibrational spectroscopy. The method can be applied for prescreening of drug candidates for targeting of specific biomolecules. The effect of the drug on the secondary structure distribution is monitored label-free in real time and provides thereby direct information about the efficacy of the potential drug.



traducir


 

ANTIBODY HIGHLY SPECIFICALLY RECOGNIZING TURN STRUCTURE AT 22- AND 23-POSITIONS IN AMYLOID β

NºPublicación: CN108064284A 22/05/2018

Solicitante:
国立大学法人京都大学,
国立大学法人千叶大学,
株式会社免疫生物研究所

Resumen de: WO2016092865A1

Provided is an antibody or an immunologically reactive fragment thereof which targets exclusively an Aβ having a specific turn structure of Aβ (a toxic conformer of Aβ). Also provided are a medicinal composition comprising, as an active ingredient, an antibody that specifically recognizes a toxic conformer of Aβ, a kit for assaying a toxic conformer of Aβ, a diagnostic agent for Alzheimer's disease, etc.



traducir


 

Alpha-Synuclein Antibodies (7A11)

NºPublicación: US2018134775A1 17/05/2018

Solicitante:
UNIV UNITED ARAB EMIRATES [AE]

Resumen de: US2018134775A1

The invention relates to an antibody or fragment thereof and the use of the antibody in a method of treatment and/or diagnosis. The antibody or fragment thereof specifically binds to alpha-synuclein, including monomeric, oligomeric and fibril forms of alpha-synuclein; is not cross reactive with beta-synuclein or gamma-synuclein; specifically binds human, rat and mouse alpha-synuclein; binds nitrated, oxidized and phosphorylated forms of alpha-synuclein; and binds an epitope of human alpha synuclein comprising the sequence MPSEEGYQDYEPEA (SEQ ID NO:2). The method for diagnosing a neurodegenerative disease associated with alpha-synuclein or for detecting alpha-synuclein, comprises adding the antibody or fragment thereof to a biological sample from a subject, and detecting the presence or absence of a complex formed between alpha-synuclein and the antibody or fragment.



traducir


 

Method of Providing Disease-Specific Binding Molecules and Targets

NºPublicación: US2018134773A1 17/05/2018

Solicitante:
UNIV OF ZUERICH [CH]
UNIV OF ZURICH [CH]

Resumen de: US2018134773A1

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.



traducir


 

METHOD FOR DETERMINING THE RISK OF DEVELOPING ALZHEIMER'S DISEASE

NºPublicación: US2018136235A1 17/05/2018

Solicitante:
CONSEJO SUPERIOR DE INVESTIG CIENTIFICAS [ES]
TETRANEURON S L [ES]

Resumen de: US2018136235A1

The present invention relates to an in vitro method for determining the risk of developing Alzheimer's disease or a cognitive disorder similar to said disease, an in vitro method for designing a personalized therapy in a subject suffering from mild cognitive impairment and an in vitro method for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer's or a cognitive disorder similar to said disease based on determining, in a sample from the subject, the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant. The invention also relates to the use of E2F4 or a functionally equivalent variant thereof, wherein the E2F4 or variant is phosphorylated in threonine as a marker of the risk of developing Alzheimer's disease or a cognitive disorder similar to Alzheimer's disease. Finally, the invention relates to a kit comprising a reagent capable of determining the level of phosphorylation in threonine residues of E2F4 protein and the use of said kit.



traducir


 

IN VITRO DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE BASED ON THE ALBUMIN REDOX LEVEL IN THE CEREBROSPINAL FLUID

NºPublicación: US2018136236A1 17/05/2018

Solicitante:
GRIFOLS WORLDWIDE OPERATIONS LTD [IE]

Resumen de: US2018136236A1

The present disclosure relates to an in vitro method for diagnosing Alzheimer's disease (AD), comprising the steps of: a) determining the content of mercaptoalbumin (HMA) in a sample of cerebrospinal fluid (CSF); and b) comparing the content determined with the content of HMA in CSF in healthy subjects. If the HMA content is less than that of the healthy subjects, it is indicative of AD.



traducir


 

METHOD FOR CLINICALLY AND PATHOLOGICALLY MONITORING ALZHEIMER'S DISEASE THROUGH CONCENTRATION OF AMYLOIDBETA IN PLASMA

NºPublicación: US2018136234A1 17/05/2018

Solicitante:
SEOUL NATIONAL UNIV R&DB FOUNDATION [KR]

Resumen de: US2018136234A1

Provided is a method for quantifying Aβ in plasma by treating the plasma with MPP and/or TCEP, and a method for diagnosing, using the quantifying method, whether or not clinical cognitive deterioration and pathological Aβ accumulation occur. Through cut-off values of measured values measured by the method for quantifying Aβ according to the present subject matter, it is possible to identify normal, MCI and AD subjects and determine whether or not accumulation of Aβ in the brain occurs, and it is possible to predict progression to AD.



traducir


 

METHODS FOR DETECTING AN INDIVIDUAL AS BEING AT RISK OF DEVELOPING A NEURODEGENERATIVE DISEASE

NºPublicación: WO2018087229A1 17/05/2018

Solicitante:
BRAIN BIOMARKER SOLUTIONS IN GOTHENBURG AB [SE]

Resumen de: WO2018087229A1

The present invention relates to a method for detecting an individual as being at risk of developing a neurodegenerative disease, the method comprising: a) measuring the amount or concentration of neurofilament-light (NfL) in a sample obtained from the individual; and b) detecting the individual as being at risk of developing the disease by comparing the amount or concentration determined in step (a) to the amount or concentration of NfL in a control, wherein an increased value of NfL relative to the control is indicative of the future development of the disease, as well as to uses related thereto.



traducir


 

PHOSPHOSPECIFIC ANTIBODIES RECOGNISING TAU

NºPublicación: CN108034005A 15/05/2018

Solicitante:
AC免疫有限公司,
勒芬天主教大学

Resumen de: WO2013050567A1

The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles, in particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).



traducir


 

ANTIBODIES TO PYROGLUTAMATE AMYLOID-β AND USES THEREOF

NºPublicación: WO2018083628A1 11/05/2018

Solicitante:
JANSSEN PHARMACEUTICA NV [BE]

Resumen de: WO2018083628A1

The invention provides an antibody or antigen binding fragments thereof that binds to 3pE Aβ and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases.



traducir


 

COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES

NºPublicación: WO2018085263A1 11/05/2018

Solicitante:
RESILIO THERAPEUTICS LLC [US]

Resumen de: WO2018085263A1

Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that can metabolize under physiological conditions to ornithine. The pH and plasma stability of compounds of formula (II) is also described. Also disclosed are methods for the treatment of neurodegenerative diseases such as Alzheimer's Disease using compounds of formula (II).



traducir


 

COMPOSITIONS TARGETING 3-REPEAT TAU FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS, AND METHODS FOR MAKING AND USING THEM

NºPublicación: WO2018085653A1 11/05/2018

Solicitante:
UNIV CALIFORNIA [US]

Resumen de: WO2018085653A1

In alternative embodiments, provided are compositions such as antibodies, e.g., single chain antibodies, that target 3-repeat (3R) Tau for the treatment of neurodegenerative disorders and taupathies such as Alzheimer's Disease (AD), Pick's Disease (PiD) and Fronto-temporal lobar degeneration (FTLD), or any disorder or condition associated with a 3R Tau accumulation, and methods for making and using them. In alternative embodiments, provided are brain-penetrating antibodies that specifically recognize 3R Tau, and methods of using them to treat, ameliorate, prevent or decrease the symptoms of neurodegenerative disorders including taupathies such as Alzheimer's Disease (AD), Pick's Disease (PiD) and Fronto-temporal lobar degeneration (FTLD), or any disorder or condition associated with a 3R Tau accumulation. Provided are methods for diagnosing a neurodegenerative disorder or a taupathy or any disorder or condition associated with a 3R Tau accumulation.



traducir


 

METHOD FOR DETERMINING RISK OF ALZHEIMER'S DISEASE

NºPublicación: WO2018084242A1 11/05/2018

Solicitante:
KYUSHU UNIV NATIONAL UNIV CORPORATION [JP]
HISAYAMA RES INSTITUTE FOR LIFESTYLE DISEASES [JP]

Resumen de: WO2018084242A1

According to the present invention, the presence or absence of a risk of acquiring Alzheimer's disease or an onset risk thereof can be determined by measuring glycoalbumin and hemoglobin A1c in a blood sample and calculating a glycoalbumin/hemoglobin A1c ratio. By using the glycoalbumin/hemoglobin A1c ratio, moreover, a compound for treating or preventing Alzheimer's disease can be screened.



traducir


 

METHOD FOR IDENTIFYING PARKINSON DISEASE DEMENTIA FROM PARKINSON DISEASE

NºPublicación: US2018128840A1 10/05/2018

Solicitante:
MAGQU CO LTD [TW]

Resumen de: US2018128840A1

The present invention provides a method for identifying Parkinson disease with normal cognition or Parkinson disease dementia in a subject.



traducir


 

USE OF APTAMERS IN THERAPY AND/OR DIAGNOSIS OF AUTOIMMUNE DISEASES

NºPublicación: US2018127757A1 10/05/2018

Solicitante:
CHARITE UNIV BERLIN [DE]
MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN [DE]

Resumen de: US2018127757A1

The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclampsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.



traducir


 

Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions

NºPublicación: US2018125920A1 10/05/2018

Solicitante:
UNIV BRITISH COLUMBIA [CA]

Resumen de: US2018125920A1

The disclosure pertains to methods of treating or preventing a disease or condition associated with and/or induced by soluble A-beta oligomer such as Alzheimer's disease by administering to a subject in need thereof conformation specific and/or selective antibodies or binding fragments thereof and related products.



traducir


 

Agents, Uses and Methods for the Treatment of Synucleinopathy

NºPublicación: US2018127492A1 10/05/2018

Solicitante:
H LUNDBECK AS [DK]

Resumen de: US2018127492A1

The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.



traducir


 

Agents, Uses and Methods for the Treatment of Synucleinopathy

NºPublicación: US2018127491A1 10/05/2018

Solicitante:
H LUNDBECK AS [DK]

Resumen de: US2018127491A1

The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.



traducir


 

METHOD FOR DIAGNOSIS OF ALZHEIMER'S DISEASE

NºPublicación: JP2018072313A 10/05/2018

Solicitante:
バイオ−ステム・バイオテック・カンパニー・リミテッドBio−Stem Biotech Co., Ltd.

Resumen de: US2018113129A1

The present invention is related to a method for risk detection, diagnosis, prognosis and monitoring of Alzheimer's disease (AD). The method comprises the steps of: (1) measuring the level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in a sample from the subject, and (2) comparing the level of GAPDH in the sample with two or more AD reference levels of GAPDH.



traducir


 

DIAGNOSTIC TEST FOR ALZHEIMER'S DISEASE BASED ON IDENTIFICATION OF A PROTEOLYTIC PATHWAY

NºPublicación: EP3316967A1 09/05/2018

Solicitante:
HEALTH RESEARCH INC [US]

Resumen de: WO2017004385A1

A method for detecting circulating levels of beta amyloid peptides in an individual by administration of one or more inhibitors of an extracellular proteolytic pathway in blood and detection of the beta amyloid peptides in the blood or a fraction thereof. An example of an inhibitor is an anticoagulant. Levels of desired beta amyloid peptides such as Αβ1-40 and Αβ1-42 can be determined in the blood samples collected from the individuals.



traducir


 

METHOD FOR DETERMINING THE RISK OF DEVELOPING ALZHEIMER'S DISEASE

NºPublicación: EP3318874A1 09/05/2018

Solicitante:
CONSEJO SUPERIOR DE INVESTIG CIENTIFICAS [ES]
TETRANEURON S L [ES]

Resumen de: EP3318874A1

The present invention relates to an in vitro method for determining the risk of developing Alzheimer's disease or a cognitive disorder similar to said disease, an in vitro method for designing a personalized therapy in a subject suffering from mild cognitive impairment and an in vitro method for selecting a patient susceptible to be treated with a therapy for the prevention and/or treatment of Alzheimer's or a cognitive disorder similar to said disease based on determining, in a sample from the subject, the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant. The invention also relates to the use of E2F4 or a functionally equivalent variant thereof, wherein the E2F4 or variant is phosphorylated in threonine as a marker of the risk of developing Alzheimer's disease or a cognitive disorder similar to Alzheimer's disease. Finally, the invention relates to a kit comprising a reagent capable of determining the level of phosphorylation in threonine residues of E2F4 protein and the use of said kit.



traducir


 

METHOD FOR DIAGNOSIS OF ALZHEIMER'S DISEASE

Nº publicación: CN107991490A 04/05/2018

Solicitante:
百欧丝丹生物科技有限公司

Resumen de: US2018113129A1

The present invention is related to a method for risk detection, diagnosis, prognosis and monitoring of Alzheimer's disease (AD). The method comprises the steps of: (1) measuring the level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in a sample from the subject, and (2) comparing the level of GAPDH in the sample with two or more AD reference levels of GAPDH.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver